^
    Back
    Association details:
    Biomarker:MMP2 overexpression
    Cancer:Pancreatic Adenocarcinoma
    Drug:gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)

    Published date:
    10/16/2023
    Excerpt:
    High MMP-2 expression was associated with better mOS (p=0.007) and longer ToT (p=0.006) in patients who received GN.